JPH03280859A - Functional food containing inulins - Google Patents
Functional food containing inulinsInfo
- Publication number
- JPH03280859A JPH03280859A JP2082839A JP8283990A JPH03280859A JP H03280859 A JPH03280859 A JP H03280859A JP 2082839 A JP2082839 A JP 2082839A JP 8283990 A JP8283990 A JP 8283990A JP H03280859 A JPH03280859 A JP H03280859A
- Authority
- JP
- Japan
- Prior art keywords
- inulins
- uric acid
- food
- blood
- functional food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001202 Inulin Polymers 0.000 title claims abstract description 14
- 235000013376 functional food Nutrition 0.000 title claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940116269 uric acid Drugs 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 7
- 229940029339 inulin Drugs 0.000 claims description 7
- 235000013305 food Nutrition 0.000 abstract description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical group OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 5
- 210000003608 fece Anatomy 0.000 abstract description 5
- 150000004676 glycans Chemical class 0.000 abstract description 3
- 229920001282 polysaccharide Polymers 0.000 abstract description 3
- 239000005017 polysaccharide Substances 0.000 abstract description 3
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 2
- 235000008078 Arctium minus Nutrition 0.000 abstract description 2
- 244000298479 Cichorium intybus Species 0.000 abstract description 2
- 235000007542 Cichorium intybus Nutrition 0.000 abstract description 2
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000000378 dietary effect Effects 0.000 description 7
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
のＩ
本発明はイヌリン類を含有する機能性食品に関するもの
で、特にそれらの添加によって血中の尿酸量の抑制機能
を有する新規の機能性食品に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to functional foods containing inulins, and particularly to novel functional foods that have the ability to suppress the amount of uric acid in the blood by adding them.
従ｍ術
医食同源という言葉からも知られるように、これまでの
食品成分あるいは栄養の問題をそれぞれ独立的に捉えら
れていた時代と異なり、予防医学の進展と共に現在は積
極的に食品成分の持つ機能を最大限生かし、食品によっ
て疾病の予防と健康の増進を計ろうとする時代となって
きている。この中で食物繊維摂取の栄養学的意義につい
てはこれまでにも多くの研究が行われ、血中コレステロ
ール値抑制、食用色素の毒性阻止、ミネラルの吸収に与
える影響についてなとの効果が明らかにされているが、
食物繊維の効果については、抱水性、膨潤性、ゲル形成
、吸着、イオン交換能なと、生体に与える機能性とこれ
らの物理化学的機能特性との関係について、まだ不明確
な点が数多く残されており、これまでのところ食物繊維
と一部成人病の予防効果との関連が明らかにされてきて
はいるものの、痛風を初めとする高尿酸血症の一因とな
る食事性核酸の消化吸収に対する食物繊維摂取の影響、
さらに食物ａｉ！の尿酸代謝に与える影響についてはい
また不明な点が多かった。As is also known from the expression, ``medicine and food are the same source,'' unlike in the past when issues of food ingredients and nutrition were considered independently, now with the advancement of preventive medicine, food ingredients are actively considered. We live in an era where we are trying to prevent diseases and promote health through food by making the most of the functions of food. Many studies have been conducted on the nutritional significance of dietary fiber intake, and the effects of suppressing blood cholesterol levels, blocking the toxicity of food dyes, and affecting the absorption of minerals have been revealed. Although it has been
Regarding the effects of dietary fiber, there are still many unclear points regarding the relationship between the functionality it provides to living organisms and these physicochemical functional properties, such as hydration, swelling, gel formation, adsorption, and ion exchange ability. Although the relationship between dietary fiber and the preventive effects of some adult diseases has been clarified so far, the digestion of dietary nucleic acids, which contributes to hyperuricemia including gout, is Effect of dietary fiber intake on absorption;
More food ai! There were still many unknowns regarding the effects of uric acid on uric acid metabolism.
が しようとする
生体内の尿酸代謝は種々の生理的要因によって変動する
ことが知られており、°食事成分としては、核酸、蛋白
質、果糖やアルコールの過剰摂取により尿酸プールが増
大することが示されている。特に食事性核酸はフリンヌ
クレオチトを経て尿酸の生成を盛んにすることが知られ
ており、高尿酸血症の治療、予防に食事性核酸や蛋白質
の摂取を制限した食＄療法が取り入れられている。It is known that in vivo uric acid metabolism varies depending on various physiological factors, and it has been shown that excessive intake of dietary components such as nucleic acids, proteins, fructose, and alcohol increases the uric acid pool. has been done. In particular, dietary nucleic acids are known to stimulate the production of uric acid via furin nucleotides, and dietary therapy that restricts the intake of dietary nucleic acids and proteins has been adopted to treat and prevent hyperuricemia. There is.
本発明者は植物繊維の−っであるイヌリンに着目し、食
事性核酸の吸収に及ぼす影響を明らかにし、イヌリン類
を含有する食品ならびに飲食物によって高尿酸血症の治
療、予防をはかろうとするものである。The present inventor focused on inulin, which is a plant fiber, and clarified its effect on the absorption of dietary nucleic acids, and attempted to treat and prevent hyperuricemia by using foods, drinks, and drinks containing inulin. It is something to do.
た の
本発明はイヌリン類を食前させることにより、食事性核
酸の利用を抑制させ、血中尿酸量上昇抑制効果ならびに
上昇予防効果を有する食品：原料あるいは食品添加物と
してイヌリン類を含有することにより、食事性核酸の摂
取を制限された高尿酸血症者に対し、核酸の摂取を予防
する効果を持たせた食品ならひにその効果を有する食品
添加組成物：
に関するもので、本発明で使用されるイヌリンは動物の
消化酵素では分解されない多糖類、つまり食物繊維の一
種であり、食品（ごぼう、チコリなと）に含有される成
分で毒性もなく、構成糖とし。The present invention suppresses the utilization of dietary nucleic acids by giving inulins before meals, and has the effect of suppressing and preventing increases in blood uric acid levels: by containing inulins as raw materials or food additives. A food additive composition that has the effect of preventing the ingestion of nucleic acids in hyperuricemic patients whose intake of dietary nucleic acids is restricted. Inulin is a polysaccharide that cannot be broken down by animal digestive enzymes, a type of dietary fiber, and is a component contained in foods (burdock, chicory, etc.), non-toxic, and is a constituent sugar.
てβ−Ｄ−フルクトースがβ−１，２結合した多糖類で
ある。一般にセルロースをはじめとする植物細胞壁由来
のこれらの１＆維は陰性の電荷を持っており、陽イオン
吸着能や多価陽イオンを介した陰イオンの吸着能を有し
ている点が特徴である。It is a polysaccharide in which β-D-fructose is linked with β-1,2 bonds. Generally, these 1&fibers derived from plant cell walls, including cellulose, have a negative charge and are characterized by their ability to adsorb cations and adsorb anions via polyvalent cations. .
本発明のイヌリン類の使用量は症状によって適宜選択で
きるが、１日１ｇ〜５０ｇ程度であり、これを食品中に
混入摂取することによって尿酸量の著しい低下をもたら
すことができるもので、このようなイヌリンの生理効果
がとのようなＩ！序で発現するかは、なお検討の必要が
あるが、１ｌｌｋ＄Ｉの陽イオン交換性に基づくプリン
塩基、プリンヌクレオシドが吸着し、糞便中に排泄され
るものと考えられる。The amount of inulin used in the present invention can be appropriately selected depending on the symptoms, but it is about 1 g to 50 g per day, and by mixing it with food and ingesting it, it can significantly reduce the amount of uric acid. The physiological effects of inulin are amazing! Although it still needs to be investigated whether it is expressed in the feces, it is thought that purine bases and purine nucleosides are adsorbed based on the cation exchange properties of 1lk$I and excreted in the feces.
九隻扁
以下に本発明の実施例を示す。なおこれらの実施例にお
いては、実験区は基本飼料（セルロース）イヌリン添加
飼料の二区分とし、それぞれのド料絹成は第１表に示す
通りであった。また実験動物とし・では５返金つィスタ
ー系雄ラットを用い、各群６または５匹とし、飼育方法
は本実験５日間、ミールフィーデングとし、採食量は各
群一定（２０ｇ）として毎日体重を測定した。Examples of the present invention are shown below. In these Examples, the experimental plots were divided into two categories: basic feed (cellulose) and inulin-added feed, and the composition of each feed was as shown in Table 1. As experimental animals, we used five-twin male rats, with 6 or 5 rats in each group.The feeding method was meal feeding for 5 days of this experiment, and the amount of food eaten was constant (20 g) in each group, and the body weight was checked every day. It was measured.
第 表 比較実験の結果は第２表に示す通りであフな。No. table The results of the comparative experiment are shown in Table 2 and are satisfactory.
なお１育期間中体重、糞、尿の状態なＩＩｉ察、２日目
に尿を採収、飼料投与５日目に動物を断首層殺し血液を
採取、内臓器官を創見した。冥駐項目の中で血漿中尿酸
、尿中尿酸と共に尿中７ラントインを測定したのは人間
では核酸代５ＩＩｋ終生成物が尿酸であるが、ラットで
は体内に尿酸をアラシドインに代謝する酵素ウリカーゼ
を育するので、同時にアラントイン排泄量をも測定した
ものである。The body weight, feces, and urine conditions were monitored during the first breeding period, and urine was collected on the second day. On the fifth day of feed administration, the animals were decapitated, blood was collected, and internal organs were discovered. Among the residual items, urinary 7 rantoin was measured along with plasma uric acid and urinary uric acid.In humans, the final product of nucleic acid 5IIk is uric acid, but in rats, the enzyme uricase, which metabolizes uric acid to aracidoin, is present in the body. At the same time, allantoin excretion was also measured.
第２表
発」ＬΩ］［釆
以上の実施例からも知られるように、本発明によれば食
品中へのイヌリンの添加によ）て平均増体重や糞の状態
に全く悪影響を及ぼすことなく、血中の尿酸量を著しく
低下させることができる。[Second expression "LΩ] [As is known from the above examples, according to the present invention, the addition of inulin to foods) does not have any adverse effect on the average weight gain or the condition of feces. , can significantly reduce the amount of uric acid in the blood.
出 代 願 理 人 人 第三化成株式会社 丸 山 幸 雄Out teenager wish Reason Man Man Daisan Kasei Co., Ltd. Yuki Maruyama
Claims (1)
を付与されていることを特徴とする機能性食品A functional food characterized by having the ability to suppress the amount of uric acid in the blood by containing inulin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2082839A JPH03280859A (en) | 1990-03-29 | 1990-03-29 | Functional food containing inulins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2082839A JPH03280859A (en) | 1990-03-29 | 1990-03-29 | Functional food containing inulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03280859A true JPH03280859A (en) | 1991-12-11 |
Family
ID=13785567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2082839A Pending JPH03280859A (en) | 1990-03-29 | 1990-03-29 | Functional food containing inulins |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03280859A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7387803B2 (en) | 1995-12-26 | 2008-06-17 | Cns, Inc. | Dietary fiber delivery system |
-
1990
- 1990-03-29 JP JP2082839A patent/JPH03280859A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7387803B2 (en) | 1995-12-26 | 2008-06-17 | Cns, Inc. | Dietary fiber delivery system |
| US7452553B2 (en) | 1995-12-26 | 2008-11-18 | Cns, Inc. | Dietary fiber delivery system |
| US7521072B2 (en) | 1995-12-26 | 2009-04-21 | Cns, Inc. | Dietary fiber delivery system |
| US7648720B2 (en) | 1995-12-26 | 2010-01-19 | Cns, Inc. | Dietary fiber delivery system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0382355B1 (en) | Growth promoting agent for bacteria containing pullulan with or without dextran | |
| JPH0120851B2 (en) | ||
| US5096894A (en) | Rice dextrin oral rehydration solution | |
| EP1212070B1 (en) | Plant extract mixtures (cissus, vernonia, brillantaisia) and their uses | |
| TWI291351B (en) | Pharmaceutical composition for lowering blood-sugar | |
| Mills et al. | The influence of lactose on calcium retention in children | |
| CN106617072A (en) | Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof | |
| JP3622985B2 (en) | How to increase magnesium absorption and prevent atherosclerosis | |
| JP2986324B2 (en) | Diet / Diabetic Food | |
| AU776376B2 (en) | Remedies for hyperammonemia | |
| KR20230119829A (en) | Animal oral solution powder composition containing astaxanthin and method for manufacturing the same | |
| JP2003048839A (en) | PREPARATION STIMULATING iNOS ENZYME INDUCTING IMMUNOREACTIVE NO SYNTHESIS AND METHOD FOR PRODUCING THE PREPARATION | |
| JPH03280859A (en) | Functional food containing inulins | |
| JPH09104624A (en) | α-Glucosidase inhibitor, sugar-based composition containing the same, sweetener, food and feed | |
| USRE36032E (en) | Rice dextrin oral rehydration solution | |
| US5773426A (en) | Proteoglucan and antidiabetic drug thereof | |
| CN116831288A (en) | Prebiotic composition and preparation method thereof and method for reducing uric acid | |
| CN1262281C (en) | Medicines, food and beverages and feeds containing cocoa components | |
| JP4307006B2 (en) | Diabetes preventive | |
| JPH03280852A (en) | Functional food containing chitin and its derivative | |
| EP2027862B1 (en) | Composition for enhancing immune function comprising zinc and a nigerooligosaccharide | |
| EP0134112A2 (en) | Pharmaceutical composition for prophylaxis or treatment of ketosis in livestock | |
| KR20220108239A (en) | Milk composition for companion animals | |
| JP2002369658A (en) | Pet food | |
| JPH0761952B2 (en) | Manufacturing method of refined wheat flour |